Galderma Group N (GALD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galderma Group N (GALD) has a cash flow conversion efficiency ratio of 0.061x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF475.06 Million ≈ $600.61 Million USD) by net assets (CHF7.73 Billion ≈ $9.77 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Galderma Group N - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Galderma Group N's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read GALD current and long-term liabilities for a breakdown of total debt and financial obligations.
Galderma Group N Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galderma Group N ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shaanxi Coal Industry Co Ltd
SHG:601225
|
0.097x |
|
KOMATSU LTD. SPONS. ADR 1
F:KOMA
|
N/A |
|
China Pacific Insurance Group Co Ltd
SHG:601601
|
0.216x |
|
People's Insurance of China Ltd
SHG:601319
|
0.146x |
|
WEG S.A
SA:WEGE3
|
0.097x |
|
PT BK CE.AS.ADR/25 RP625
F:BZG
|
0.041x |
|
UltraTech Cement Limited
NSE:ULTRACEMCO
|
0.073x |
|
Commerzbank AG
F:ZZMS
|
-0.215x |
Annual Cash Flow Conversion Efficiency for Galderma Group N (2021–2024)
The table below shows the annual cash flow conversion efficiency of Galderma Group N from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Galderma Group N.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF7.79 Billion ≈ $9.85 Billion |
CHF429.77 Million ≈ $543.34 Million |
0.055x | +67.62% |
| 2023-12-31 | CHF4.52 Billion ≈ $5.71 Billion |
CHF148.64 Million ≈ $187.92 Million |
0.033x | +28.01% |
| 2022-12-31 | CHF4.13 Billion ≈ $5.23 Billion |
CHF106.30 Million ≈ $134.39 Million |
0.026x | -40.45% |
| 2021-12-31 | CHF4.14 Billion ≈ $5.24 Billion |
CHF178.92 Million ≈ $226.21 Million |
0.043x | -- |
About Galderma Group N
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epi… Read more